Alzheimer’s drug Leqembi granted full FDA approval:
Medicare administrator, Chiquita Brooks-LaSure, said in a statement Thursday the program will begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements, including enrollment in a federal registry to track the drug’s real-world safety and effectiveness.
Some Medicare patients could be responsible for paying the standard 20% of the cost of Leqembi, though the amount will vary depending on their plans and other coverage details. Doctors need to confirm that patients have the brain plaque targeted by Leqembi before prescribing it. Nurses need to be trained to administer the drug and patients must be monitored with repeated brain scans to check for swelling or bleeding. The imaging and administration services carryEisai has told investors that about 100,000 Americans could be diagnosed and eligible to receive Leqembi by 2026. The drug is co-marketed with Cambridge, Massachusetts-based Biogen.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
First Alzheimer's drug to slow disease, Leqembi, gets full FDA approvalLeqembi is not a cure, but it is the first drug shown to slow the progression of Alzheimer's disease. It first received an accelerated approval from the FDA earlier this year.
Weiterlesen »
FDA grants full approval to Leqembi, first drug to slow progress of Alzheimer'sThe U.S. Food and Drug Administration announced full approval of lecanemab for early-stage Alzheimer's.
Weiterlesen »
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drugLeqembi is the first Alzheimer's antibody treatment to receive full FDA approval.
Weiterlesen »
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Weiterlesen »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Weiterlesen »
Alzheimer’s drug Leqembi granted full FDA approvalUPDATE: U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Weiterlesen »